{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:31:02Z","timestamp":1789133462073,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ymthe.2024.05.033","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T23:31:51Z","timestamp":1716593511000},"page":"2052-2063","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Clinical immunogenicity outcomes from GENEr8-1, a phase 3 study of valoctocogene roxaparvovec, an AAV5-vectored gene therapy for hemophilia A"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1350-0293","authenticated-orcid":false,"given":"Brian R.","family":"Long","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara M.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan R.S.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urooj","family":"Imtiaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn S.","family":"Patton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"de Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Henshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Vettermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Zoog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumi","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.05.033_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.ymthe.2024.05.033_bib2","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/hae.14304","article-title":"Patients' and parents' satisfaction with, and preference for, haemophilia A treatments: a cross-sectional, multicentre, observational study","volume":"27","author":"Park","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.ymthe.2024.05.033_bib3","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40271-019-00395-6","article-title":"Patient perspectives on novel treatments in haemophilia: a qualitative study","volume":"13","author":"van Balen","year":"2020","journal-title":"Patient"},{"key":"10.1016\/j.ymthe.2024.05.033_bib4","first-page":"1687","article-title":"Patient and parent preferences for characteristics of prophylactic treatment in hemophilia","volume":"9","author":"Furlan","year":"2015","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.ymthe.2024.05.033_bib5","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1182\/blood-2012-10-462200","article-title":"Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant","volume":"121","author":"McIntosh","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.05.033_bib6","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ymthe.2017.12.009","article-title":"Gene therapy with BMN 270 results in therapeutic levels of FVIII in mice and primates and normalization of bleeding in hemophilic mice","volume":"26","author":"Bunting","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.05.033_bib7","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.05.033_bib8","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.05.033_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtha.2024.04.001","article-title":"Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A","author":"Madan","year":"2024","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2024.05.033_bib12","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV vector immunogenicity in humans: a long journey to successful gene transfer","volume":"28","author":"Verdera","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.05.033_bib13","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.05.033_bib14","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1089\/hum.2021.287","article-title":"Global seroprevalence of pre-existing immunity against AAV5 and other AAV serotypes in people with hemophilia A","volume":"33","author":"Klamroth","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.05.033_bib15","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.omtm.2019.03.006","article-title":"The impact of pre-existing immunity on the non-clinical pharmacodynamics of AAV5-based gene therapy","volume":"13","author":"Long","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2024.05.033_bib16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ymthe.2005.08.017","article-title":"Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates","volume":"13","author":"Gao","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.05.033_bib17","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/gt.2017.95","article-title":"Strategy to detect pre-existing immunity to AAV gene therapy","volume":"24","author":"Falese","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2024.05.033_bib18","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-factor VIII gene transfer in severe hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.05.033_bib19","doi-asserted-by":"crossref","first-page":"316","DOI":"10.2174\/156652307782151425","article-title":"Immune responses to AAV in clinical trials","volume":"7","author":"Mingozzi","year":"2007","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.05.033_bib20","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nm1549","article-title":"CD8(+) T-cell responses to adeno-associated virus capsid in humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.05.033_bib21","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.05.033_bib22","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1172\/JCI36891","article-title":"Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors","volume":"119","author":"Pien","year":"2009","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2024.05.033_bib23","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.05.033_bib24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.05.033_bib25","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/hae.14391","article-title":"Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A","volume":"27","author":"Pasi","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.ymthe.2024.05.033_bib26","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/hae.14936","article-title":"Long-term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post-treatment","volume":"30","author":"Symington","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.ymthe.2024.05.033_bib27","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ymthe.2020.12.008","article-title":"Early phase clinical immunogenicity of valoctocogene roxaparvovec, an AAV5-mediated gene therapy for hemophilia A","volume":"29","author":"Long","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.05.033_bib29","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1182\/bloodadvances.2020002731","article-title":"The prospective hemophilia inhibitor PUP study reveals distinct antibody signatures prior to FVIII inhibitor development","volume":"4","author":"Reipert","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2024.05.033_bib30","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2024.05.033_bib31","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1182\/blood-2014-09-598268","article-title":"Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans","volume":"125","author":"Hofbauer","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.05.033_bib32","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2012-07-444877","article-title":"Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients","volume":"121","author":"Whelan","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.05.033_bib33","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1089\/hum.2022.138","article-title":"Immune responses and immunosuppressive strategies for adeno-associated virus-based gene therapy for treatment of central nervous system disorders: current knowledge and approaches","volume":"33","author":"Prasad","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.05.033_bib34","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa1000228","article-title":"Dystrophin immunity in Duchenne's muscular dystrophy","volume":"363","author":"Mendell","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.05.033_bib35","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.omtm.2021.05.012","article-title":"Monitoring cell-mediated immune responses in AAV gene therapy clinical trials using a validated IFN-gamma ELISpot method","volume":"22","author":"Patton","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624003356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624003356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T12:02:30Z","timestamp":1737633750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001624003356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1525001624003356"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.05.033","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical immunogenicity outcomes from GENEr8-1, a phase 3 study of valoctocogene roxaparvovec, an AAV5-vectored gene therapy for hemophilia A","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.05.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}